Abstract:BACKGROUND: Diverse clinical and serological manifestations of systemic lupus erythematosus (SLE) compromise its diagnosis and treatment. A more reliable biomarker for SLE, which can play a critical role in either diagnosis, monitoring the disease progress or evaluating the response to treatment for individualized therapeutic, is necessary. DNA sensor is an important mediator of inflammation in systemic autoimmune diseases. However, the potential role for DNA sensor as disease activity biomarkers for SLE remained obscure. We detected the aberrant activation of DNA sensors and the corresponding IFN-β response in SLE patients, and to evaluate their potential role as disease biomarkers for SLE.METHODS: We quantified the expressions of IFN-I and DNA sensor, such as cGAS, IFI16, DDX41, DAI and their down-stream adaptor STING in PBMC derived from patients with SLE (n = 100), healthy controls (HCs) (n = 62) by real-time PCR. The relationships between the expression of cGAS or IFI16 and clinical features in SLE patients were investigated. ROC curve analysis was performed to examine the predictive value of cGAS and IFI16 in SLE diagnosis, disease activity monitoring, specific organ manifestation and therapeutic response. RNA interference-mediated depletion of IFI16 or cGAS was conducted to evaluate their impact on IFN-I response.RESULTS: The expressions of cGAS and IFI16 were significantly higher in PBMC from SLE patients, closely correlated with the SLEDAI scores and high anti-dsDNA antibody titers. While the AUC for cGAS (0.767) was less than that of IFI16 and IFN-β, the AUC for IFI16 (0.856) and IFN-β (0.856) were similar. Expression of cGAS and IFI16 combine with IFN-β in PBMC showed high sensitivity (89.2%) and specificity (89.1%) for discrimination between mild and moderate/severe disease activity in SLE. Higher expression of IFI16 was association with ocular disorder in SLE patients. Neither IFI16 nor cGAS was a reliable indicator of therapeutic response. RNA interference-mediated depletion of IFI16 or cGAS prevented active SLE serum-induced upregulating in both IFN-α and IFN-β.CONCLUSIONS: High expression levels of cGAS and IFI16 in PBMC from SLE patients correlated strongly with disease activity. Both cGAS and IFI16 mediated signaling pathway were account for the robust production of IFN-β. Expression of cGAS and IFI16 combined with IFN-β in PBMC might serve as potential biomarkers for early diagnosis and monitoring disease activity in SLE.

[Evaluating Type I Interferon-Inducible Gene Expression in Patients with Systemic Lupus Erythematosus.].

Increased interferon-inducible gene expression, an useful marker in the diagnosis and disease activity evaluation of systemic lupus erythematosus

Identification of Interferon-Inducible Genes As Diagnostic Biomarker for Systemic Lupus Erythematosus

Association Of Increased Interferon-Inducible Gene Expression With Disease Activity And Lupus Nephritis In Patients With Systemic Lupus Erythematosus

Dysregulated T Cell Activation and Aberrant Cytokine Expression Profile in Systemic Lupus Erythematosus.

Expressions of interferon-inducible genes in patients with systemic lupus erythematosus and their assoc-iation with disease activity

lncRNA X-inactive-specific transcript is a potential biomarker related to changes in CD4 + T cell levels in systemic lupus erythematosus

Identification of key interferon-stimulated genes for indicating the condition of patients with systemic lupus erythematosus

LncRNA XIST Alters the Balance of Peripheral Blood Immune Cells in Systemic Lupus Erythematosus by Regulating the miR-17-92/OFLM4 and CEACAM8 Axis

Validate the Abnormality of Interferon-Inducible Gene Expression Spectrum in Systemic Lupus Erythematosus Patients Using Real- Time PCR

Characterization of CD4+ T cells expressing an elevated interferon-stimulated gene signature in SLE patients

IRF4 and IRGs Delineate Clinically Relevant Gene Expression Signatures in Systemic Lupus Erythematosus and Rheumatoid Arthritis

Expression level of Interferon regulatory factor 5 in systemic lupus erythematosus

The role of cyclic GMP-AMP synthase and Interferon-I-inducible protein 16 as candidatebiomarkers of systemic lupus erythematosus

Protein Interaction for an Interferon-Inducible Systemic Lupus Associated Gene, IFIT1

Optimal Selection of IFN-α-Inducible Genes to Determine Type I Interferon Signature Improves the Diagnosis of Systemic Lupus Erythematosus

Levels of Soluble Interleukin-2 Receptor and Clinical Significance in Patients with Systemic Lupus Erythematosus

The study on the expression of EBV antibody in patients with systemic lupus erythematosus

Expression of Cyclic GMP-AMP Synthase in Patients With Systemic Lupus Erythematosus

Identification and Validation of IFI44 As Key Biomarker in Lupus Nephritis.

Type I Interferon Predicts an Alternate Immune System Phenotype in Systemic Lupus Erythematosus